Covid-19 Vaccine India: Vaccine maker Bharat Biotech said on Wednesday that its COVID-19 vaccine Covaxin showed an interim vaccine capacity of 81 per cent in Phase III clinical trials. The company said in a statement that 25,800 subjects participated in the trial and this has been the largest trial ever conducted in India. According to the company, this has been done in agreement with the Indian Council of Medical Research.
Will also fight against new variants
Krishna Eela, chairman and managing director of Bharat Biotech, said that vaccine discovery today is an important milestone for science and in our fight against the coronavirus. Today, with the results of our Phase III clinical trial, we now have data on the COVID 19 vaccine from Phase 1, 2 and 3 trials, which includes about 27,000 participants. He further stated that Covaxin shows a trend of greater clinical potential against COVID-19 and, together with sufficient immunogenicity, against rapidly emerging variants.
Covaxin has been developed indigenously by Bharat Biotech under the agreement with the Indian Council of Medical Research (ICMR). The Covaxin and the covishield of Oxford-AstraZeneca are two vaccines that are being planted in the country.
Now two vaccines approved in India
Currently, the Drug Controller General of India (DGCI), the Indian drug regulator, has approved the use of two coronavirus vaccines in the country, including Covishield of SII and Kovicin of Bharat Biotech. DGCI has given emergency approval to Bharat Biotech based on the results of Phase 1 and Phase 2 trials. With this, the company also submitted the interim data for the Phase 3 trial to the regulator. The DGCI had said that the decision to grant emergency approval to the vaccine maker was based on the earlier stages of the clinical trial.